No Data
Zhongguancun: 2024 Annual Report Summary
Zhongguancun: 2024 Annual Report
Beijing Centergate Technologies (000931.SZ): The net income for 2024 is 53.5922 million yuan, an increase of 10.33% year-on-year.
Gelonghui April 17丨Beijing Centergate Technologies (000931.SZ) announced its 2024 annual report, with the company achieving revenue of 2.532 billion yuan in 2024, a year-on-year increase of 11.22%; Net income attributable to shareholders of the listed company was 53.5922 million yuan, a year-on-year increase of 10.33%; Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 32.6895 million yuan, a year-on-year decrease of 7.54%; Basic EPS was 0.0712 yuan.
Beijing Centergate Technologies (000931.SZ): The marketing authorization application for ShanDong Huasu Bisoprolol Amlodipine Tablets has been accepted.
On April 16, Glorious Holdings announced that its subsidiary, ShanDong Huasu Pharmaceutical Co., Ltd. (abbreviated as ShanDong Huasu), recently received the Acceptance Notice issued by the National Medical Products Administration, and the application for market approval of Bisoprolol Amlodipine Tablets (Specification: Bisoprolol Fumarate 5mg and Amlodipine Besilate (calculated as Amlodipine) 5mg) has been accepted. Bisoprolol Amlodipine Tablets are used as an alternative therapy for hypertension, intended for patients who are currently treated with the same dosage as a combination preparation and have well-controlled blood pressure. Bisoprolol Amlodipine Tablets have a fixed dose of fumarate.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Beijing Centergate Technologies (000931.SZ): Beijing Huazu Salt Hydrochloride Naloxone Injection selected for centralized procurement.
On April 2, Gelonghui reported that Beijing Centergate Technologies (000931.SZ) announced that its subsidiary, Peking Huasu Pharmaceutical Co., Ltd. (referred to as: Peking Huasu), participated in the tenth batch of national organized Pharmaceutical centralized procurement work. According to the notice recently released by the National Organization for Pharmaceutical Joint Procurement Office regarding the announcement of the selected results for national Pharmaceutical centralized procurement (GY-YD2024-2), the naloxone hydrochloride injection produced by Peking Huasu was selected for this centralized procurement.